A closer look at calcium antagonist;Kalziumantagonisten naher betrachtet

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 17, 2000, Pages 531-533

  Berkels, R ^a   Klaus, W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; NITRIC OXIDE SYNTHASE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; NITRIC OXIDE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DRUG MECHANISM; ENDOTHELIUM; HYPERTENSION; THROMBOCYTE; THROMBOSIS; ANIMAL; ARTERIOSCLEROSIS; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; BLOOD PLATELETS; CALCIUM CHANNEL BLOCKERS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; PLATELET AGGREGATION;

EID: 0034724853     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024315     Document Type: Article

References (45)

1. Atlas, D., M. Adler: Alpha-adrenergic antagonists as possible calcium channel inhibitors. proc. Natl. Acad. Sci. 79 (1981), 1237-1241.
2. Berkels, R., A. Bertsch, T. Breitenbach, W. Klaus: The calciumantagonist nifedipine stimaltes endothelial NO release in therapeutical concentrations. Pharm. Pharmacol. Lett. 6 (1996), 75-78.
3. Berkels, R., A. Bertsch, T. Zuther, S. Dhein, K. Stockklauser, P. Rosen, R. Rosen: Evidence for a NO synthae in porcine platelets which is stimulated during activatio/aggregation. Eur. J. Haematol. 58 (1997), 307-313.
4. Berkels, R., U. Hass, C. Dachs, W. Klaus: The calciummodulator nifedipine inhibits the endothelial uptake of modified LDL. fundamental Clin. Pharmacol. 13 (1999), 121.
5. Berkels, R., W. Klaus, M. Boller, R. Rosen: The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb. Haemost. 72 (1994), 309-312.
6. i and NO in endothelial cells. J. Cardiovasc. Pharmacol. 4 (1999), 175-181.
7. Berkels, R., R. Roesen, S. Dhein, U. Fricke, W. Klaus: Dihydropyridine calcium antagonist induced modulation of endothelial function - a review. Cardiovasc. Drug. Rev. 17 (1999), 179-186.
8. i and NO formation in endothelial cells via a kinase dependent mechanism. J. Mol. Cardiol. 30 (1998), A193.
9. Borhani, N. O., et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial [see comments]. J. Amer. med. Ass. 276 (1996), 785-791.
10. Brown, A. S., J. F. Martin: The megakaryocyte platelet system and vascular disease. Eur. J. Clin. Invest. 24 (Suppl. 1) (1994), 9-15.
11. Dhein, S., Y. Zhao, S. Simsek, A. Salameh, W. Klaus: Actions of 1,4-dihydropyridines in isolated mesenteric vascular beds. J. Cardiovasc. Pharmacol. 26 (1995), 784-191.
12. Doyle, V. M., U. T. Ruegg: Lack of evidence for voltage dependent calsium channels on platelets. Biochem. Biophys. Res. Commun. 127 (1985), 161-167.
13. Drexler, H.: Endothelial dysfunction: clinical implications. Prog. Cardiovasc. Dis. 39 (1997), 287-324.
14. Esterbauer, H., R. Schmidt, M. Hayn: Relationships among oxidation of low-density lipoprotein, antioxidant protection, and atherosclerosis. Adv. Pharmacol. 38 (1997), 425-456.
15. Fitscha, P., F. Rauscha, A. Keiler, H. Sinzinger: Isradipine inhibits mitotic and proliferative activity in the arterial wall. Exp. Toxicol. Pathol. 46 (1994), 75-80.
16. Fleckenstein, A., H. Kammermeier, H. J. Doring, H. J. Freund: On the method of action of new types of coronary dilatators with simultaneous oxygen-saving myocardial effects, prenylamine and iproveratril. 2. Z. Kreislaufforsch. 56 (1967), 839-858.
17. Fleckenstein-Grun, G., F. Thimm, A. Czirfuzs, S. Matyas, M. Frey: Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. J. Cardiovasc. Pharmacol. 24 (Suppl. 2) (1994), S75-84.
18. Frishman, W. H.: Current status of calcium channel blockers. Curr. Probl. Cardiol. 19 (1994), 637-688.
19. Gunther, J., S. Dhein, R. Rosen, W. Klaus, U. Fricke: Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res. Cardiol. 87 (1992), 452-460.
20. Haller, H., D. Schaper, W. Ziegler, S. Philipp, M. Kuhlmann, A. Distler, F. C. Luft: Low-density lipoprotein induces vascular adhesion molecule expression on human endothelial cells. Hypertension 25 (1995), 511-516.
21. Henry, P. D., K. I. Bentley: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J. Clin. Invest. 68 (1981), 1366-1369.
22. Johnson, G. J., L. A. Leis, G. S. Francis: Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619. Thromb. Res. 59 (1990), 139-148.
23. Joseph, G., Y. Zhao, C. Glaser, W. Klaus: NO dependent effects of nifedipine and nitrendipine in isolated guinea pig hearts. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997), R 40.
24. Kataoka, S., r. alam, P. K. Dash, F. M. Yatsu: Inhibition of PDGF-mediated proliferation of vascular smooth muscle cells by calcium antagonists. Stroke 28 (1997), 364-369.
25. Klaus, W., R. Berkels, S. Dhein, U. Fricke, G. Joseph, R. Rösen, A. Salameh, Y. Zhao: Endothelium-dependent actions of dihydropyridine calcium antagonists. In: Vascular Endothelium Physiology, Pathology, and Therapeutic Opportunities (Schattauer: Stuttgart 1997), 261-271.
26. Klaus, W., G. Latta, K. Schrör: The influence of nifedipine on platelet function. In: Recent Aspects in Calcium Antagonism (Schattauer: Stuttgart 1985), 139-145.
27. Kojda, G., W. Klaus, G. Werner, U. Fricke: The influence of endothelium on the action of PGF2 alpha and some dihydropyridine-type calcium antagonists in porcine basilar arteries. Basic Res. Cardiol. 86 (1991), 254-265.
28. Lichtlen, P. R., P. G. Hugenholtz, W. Rafflenbeul, H. Hecker, S. Jost, J. W. Deckers: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators (see comments). Lancet 335 (1990), 1109-1113.
29. Mak, I. T., W. B. Weglicki: Antioxidant activity of calcium channel blocking drugs. Methods Enzymol. 234 (1994), 620-630.
30. Malinski, T., M. W. Radomski, Z. Taha, S. Moncada: Direct electrochemical measurement of nitric oxide released from human platelets. Biochem. Biophys. Res. Commun. 194 (1993), 960-965.
31. 2 production by platelets without changing aggregation in hypertensive pregnancy. Pharmacol. Toxicol. 78 (1996), 387-391.
32. Moncada, S., R. M. Palmer, E. A. Higgs: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991), 109-142.
33. Mugge, A., T. Peterson, D. G. Harrison: Release of nitrogen oxides from cultured bovine aortic endothelial cells is not impaired by calcium channel antagonists. Circulation 83 (1991), 1404-1409.
34. Nayler, W. G.: Therapeutic approaches to the control of coronary atherosclerosis. Basic Res. Cardiol 89 (Suppl. 1) (1994), 137-143.
35. Norman, J. A., J. Ansell, M. A. Phillips: Dihydropyridine Ca2+ entry blockers selectively inhibit peak I cAMP phosphodiesterase. Eur. J. Pharmacol. 83 (1983), 107-112.
36. Radomski, M. W., R. M. Palmer, S. Moncada: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. 87 (1990), 5193-5197.
37. Rostagno, C., R. Abbate, G. F. Gensini, M. Coppo, D. Prisco, M. Boddi, G. G. Neri Serneri: In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. Thromb. Res. 63 (1991), 457-462.
38. Rump, A. F., M. Boller, R. Berkels, R. Rosen, U. Fricke, W. Klaus: Comparative effects of the dihydropyridine-type calcium-agonists (-)-S-Bay K 8644, (+/-)-Bay-W 5035 and (+/-)-Bay-T 5006 on human platelet aggregability. Gen Pharmacol. 25 (1994), 447-450.
39. Salameh, A., G. Schomecker, K. Breitkopf, S. Dhein, W. Klaus: The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br. J. Pharmacol. 118 (1996), 1899-1904.
40. Salomone, S., C. L. Silva, N. Morel, T. Godfraind: Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch. Pharmacol. 354 (1996), 505-512.
41. Shimokawa, H.: Primary endothelial dysfunction: atherosclerosis. J. Mol. Cell. Cardiol. 31 (1999), 23-37.
42. Vilaine, J. P., M. L. Biondi, N. Villeneuve, M. Feletou, J. L. Peglion, P. M. Vanhoutte: The calcium channel antagonist S 11568 causes endothelium-dependent relasxation in canine arteries. Eur. J. Pharmcol. 197 (1991), 41-48.
43. Wagenknecht, L. E., C. D. Furberg, J. W. Hammon, C. Legault, B. T. Troost: Surgical bleeding: unexpected effect of a calcium antagonist (see comments). Brit. med. J. 310 (1995), 776-777.
44. Waters, D., et al.: A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis (see comments). Circulation 82 (1990), 1940-1953.
45. Zhang, X., T. H. Hintze: Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected machanism of action of a calcium channel-blocking agent. Curculation 97 (1998), 576-580.